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Results In total, 31 patients were enrolled. Median 
(range) treatment duration with everolimus was 76 days 
(1–431). Principal grade 3/4 toxicities were hyperglyce-
mia (45 %), hand-foot syndrome (16 %), diarrhea (6 %) 
and mucositis (3 %). Prominent grade 1/2 toxicities were 
anemia (81 %), rash (65 %), mucositis (58 %) and fatigue 
(55 %). RR was 6 %. Ten patients (32 %) had stable disease 
resulting in a disease control rate of 38 %. Median overall 
survival was 8.9 months (95 % CI 4.6–13.1). Progression-
free survival was 3.6 months (95 % CI 1.9–5.3).
Conclusions The oral regimen with the combination of 
capecitabine and everolimus is a moderately active treat-
ment for patients with advanced pancreatic cancer, with an 
acceptable toxicity profile at the applied dose level.
Keywords mTOR · Pancreatic cancer · Capecitabine · 
Phase II · Targeted therapy · Everolimus
Introduction
The PI3K/Akt pathway is an important intracellular signal-
ing pathway that is often dysregulated in cancer [1]. Signal 
transduction of activated PI3K/Akt is transmitted through 
several downstream targets, including the mammalian 
target of rapamycin (mTOR) [2, 3]. Everolimus, an oral 
mTOR inhibitor, has demonstrated antitumor properties in 
vitro and in vivo including inhibition of cell proliferation, 
cell survival and angiogenesis and showed additive as well 
as synergistic effects when combined with other anticancer 
agents such as 5-fluorouracil (5-FU) [4–11].
Single-agent everolimus has been investigated in 
phase I–III clinical trials in patients with various types of 
advanced solid tumors [12–19]. These trials demonstrated 
that treatment with everolimus at 10 mg daily was well 
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5-fluorouracil-based anticancer therapy is attractive 
because of preclinical evidence of synergy between these 
drugs. According to our phase I study, the combination 
of capecitabine and everolimus is safe and feasible, with 
potential activity in pancreatic cancer patients.
Methods Patients with advanced adenocarcinoma of 
the pancreas were enrolled. Eligible patients had a WHO 
performance status 0–2 and adequate hepatic and renal 
functions. The treatment regimen consisted of capecit-
abine 1000 mg/m2 BID day 1–14 and everolimus 10 mg 
daily (5 mg BID) in a continuous 21-day schedule. Tumor 
assessment was performed with CT-scan every three cycles. 
Primary endpoint was response rate (RR) according to 
RECIST 1.0. Secondary endpoints were progression-free 
survival, overall survival and 1-year survival rate.
S. Kordes and H. J. Klümpen have contributed equally to this 
work.
 * S. Kordes 
 silkordes@gmail.com
1
 Department of Medical Oncology, Academic Medical Center 
Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
2
 Division of Clinical Pharmacology, Department of Medical 
Oncology, The Netherlands Cancer Institute, Plesmanlaan 
121, Amsterdam, The Netherlands
3
 Department of Experimental Therapy, The Netherlands 
Cancer Institute, Plesmanlaan 121, Amsterdam,  
The Netherlands
4
 Division of Biomedical Analysis, Department 
of Pharmaceutical Sciences, Faculty of Science, University 
Utrecht, Universiteitsweg 99, Utrecht, The Netherlands
1136 Cancer Chemother Pharmacol (2015) 75:1135–1141
1 3
tolerated and showed clinical activity in some malignan-
cies with an acceptable toxicity profile, consisting mainly 
of stomatitis and fatigue.
Clinical trials investigating everolimus in combina-
tion with other anticancer drugs have been performed or 
are ongoing, in short, confirming preclinical evidence that 
everolimus may be more efficacious when used in com-
bination with other anticancer drugs [20–25]. Recently, a 
phase II study with the combination of low-dose capecit-
abine (650 mg/m2 BID day 1–14) and everolimus (5 mg 
BID) showed effectivity in heavily pretreated gastric cancer 
patients, and with an acceptable toxicity profile [26]. Pre-
viously, we demonstrated the safety and feasibility of the 
combination of capecitabine 1000 mg/m2 BID day 1–14 
and continuous everolimus 5 mg BID in a 21-day schedule 
[27]. In this phase I study, two out of three patients with 
pancreatic cancer achieved a partial remission (PR).
In the pre-FOLFIRINOX era, gemcitabine was consid-
ered standard therapy for first-line treatment of pancreatic 
cancer patients, because of a significant improvement of the 
clinical benefit response, although the survival advantage 
was <1 month, in comparison with 5-FU [28, 29]. Although 
studies with the oral 5-FU analogue capecitabine in direct 
comparison with 5-FU or gemcitabine in patients with pan-
creatic cancer are not available, capecitabine seems to have 
comparable activity in this patient group [30].
In the present phase II study, we explored the activity of 
capecitabine and everolimus combination treatment as first- 




Eligible patients were aged ≥18 years, with histologi-
cally or cytologically confirmed advanced pancreatic 
cancer, and measurable lesions according to Response 
Evaluation Criteria in Solid Tumors (RECIST 1.0) [31]. 
Patients who had prior chemotherapy in the adjuvant set-
ting or for metastatic disease were eligible. Adjuvant 
patients were considered second line if the chemotherapy 
free interval was <6 months before start study. Other eli-
gibility criteria included WHO performance status ≤2, 
estimated life expectancy of ≥3 months, adequate bone 
marrow (white blood cell count ≥ 3.0 × 109/L, plate-
lets ≥ 100 × 109/L) and adequate hepatic and renal func-
tion (serum bilirubin ≤ 1.5 × upper limit of normal (ULN), 
ALAT/ASAT ≤ 2.5 × ULN or in case of liver metasta-
ses ≤ 5 × ULN and serum creatinine ≤ 150 μmol/L). 
Patients were ineligible if they had established alcohol 
abuse, drug addiction and/or psychotic disorders that made 
adequate follow-up unlikely. Women who were pregnant 
or lactating were also excluded. All patients gave written 
informed consent. The study was approved by the Medical 
Ethics Committee of the Academic Medical Center Amster-
dam and was conducted in accordance with the Declaration 
of Helsinki and Good Clinical Practice guidelines. The 
trial was registered online (ClinicalTrials.gov identifier: 
NCT01079702).
Study design and treatment
This was a phase II, open-label, single-center study to 
assess the antitumor activity and safety of the combination 
of everolimus and capecitabine. The primary endpoint was 
response rate. The study was conducted at the Amsterdam 
Medical Center, The Netherlands. Everolimus was admin-
istered continuously at an oral dose of 5 mg BID. The first 
7 days of treatment patients were treated with single-agent 
everolimus to reach steady-state drug concentrations. Treat-
ment with capecitabine 1000 mg/m2 BID started on day 8 
and was given twice daily for 14 days in a three weekly cycle. 
Toxicity was graded using the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events (CTCAE) ver-
sion 3.0 and was assessed every treatment cycle [32]. Tumor 
measurements were performed at baseline and every three 
cycles, and responses were evaluated in accordance with 
RECIST 1.0 [31]. Patients continued treatment until disease 
progression, withdrawal of consent or in case of intolerabil-
ity. Overall survival was defined from start of study treatment 
until death. Progression-free survival was defined from start 
of study to clinical or radiological progression or death. When 
treatment was discontinued due to other reasons, date of last 
documented assessment was used and censored.
Statistical analysis
For sample size calculations, the two-stage design accord-
ing to Gehan for estimating the response rate was used [33]. 
In the first stage, 14 patients were entered. If no responses 
were observed in the first stage, then the trial would be ter-
minated because the absence of response (0/14) has a prob-
ability <0.05 if the true response rate is 0.20. We choose 
for an estimate with approximately a 10 % standard error, 
with an accrual of 11 patients in the second stage. For the 
evaluation of the safety, efficacy parameters descriptive sta-
tistics were applied using SPSS statistics. Intention to treat 
analysis was used.
Results
In total, 31 patients with advanced pancreatic cancer were 
enrolled between June 2010 and November 2011. After a 
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partial response in the first stage of 14 patients, 11 patients 
were enrolled in the second stage. Six additional patients 
were enrolled to ensure 25 patients receiving at least one 
full cycle of the treatment combination for a complete 
safety analysis (see below).
Patient characteristics are listed in Table 1. The major-
ity of patients had metastatic adenocarcinoma and a WHO 
performance status of 0–1. The study group consisted of 
15 first-line patients and 16 second-line patients. Eighteen 
patients received prior gemcitabine-based chemotherapy; 
11 in palliative setting, six adjuvant (five patients with 
chemotherapy free interval <6 months) and 1 as part of 
neoadjuvant chemoradiotherapy.
Overall, a total of 147 treatment cycles were given, with 
a median (range) of 3 (1–9) cycles per patient. Median 
(range) treatment duration with everolimus was 76 (1–431) 
days (Table 2). Six patients temporarily interrupted treat-
ment with everolimus due to adverse events. Following 
treatment interruption, five patients received a 50 % dose 
reduction of everolimus and the other continued treat-
ment at the full dose of everolimus. Due to adverse events, 
treatment with capecitabine was interrupted in 15 patients 
resulting in dose reductions for capecitabine in 14 patients.
Safety
Six patients did not receive a complete cycle of the treat-
ment combination; two patients refusal, three patients had 
early clinical progression, and one patient died of non-
treatment-related septic cholangitis. Treatment-related tox-
icities of these patients were included in the intention to 
treat toxicity analysis.
Table 3 lists the treatment-related CTC grade 1–2 and 
grade 3–4 adverse events. The most frequently reported 
clinical toxicities of any grade included mucositis, skin 
reactions, fatigue, nausea and diarrhea. Severe clinical tox-
icities were not frequent. Grade 3–4 hand-foot syndrome 
was observed in five patients, diarrhea in two patients, 
stomatitis, skin rash and vomiting in one patient. Three 
patients developed grade 3 hematological toxicity (throm-
bocytopenia and anemia). Hyperglycemia of any grade was 
the most frequently reported biochemical toxicity, result-
ing in clinical relevance (grade 3) in fourteen patients. 
Grade 3 levels of alkaline phosphatase, hypokalemia and 
hyperbilirubinemia occurred in two, five and one patients, 
respectively.
Antitumor activity
A total of 31 participating patients had measurable disease 
according to RECIST 1.0 at start of treatment. Nine of these 
31 patients were not available for radiological response eval-
uation due to early discontinuation of the study medication 
prior to the first planned radiological evaluation time point 
and were considered as progressive. Two patients had a par-
tial response (6.5 %). Ten patients had stable disease (32 %), 
and nineteen patients were progressive (61 %) (Table 4).
In first-line patients, PR and SD were seen in 2 (13 %) 
and 8 (53 %), respectively. In second-line patients, no 
patients had PR and 2 (13 %) patients had SD. The water-
fall plot shows radiologic responses for all radiologic eval-
uable patients (Fig. 1).
Among the nine patients who discontinued treatment early 
and who were not available for the first radiological response 
evaluation, two patients refused further therapy, three patients 
had clinical progressive disease and one patient developed 
grade 3 diarrhea and had deterioration of the performance 
status. Three patients died before radiological evaluation, two 
patients due to tumor progression and one patient died of non-
treatment-related septic cholangitis during the first cycle 
At the time of the intention to treat analysis, one 
patient was still alive. For the entire cohort, the one-year 
Table 1  Patient characteristics
WHO World Health Organization, CRT chemoradiotherapy
a
 Progression during or within 6 months after adjuvant treatment
N %
No. of patients 31
Gender
 Male 15 48
 Female 16 52
Race
 Caucasian 30 97
 Asian 1 3
Median age (years) 63
 Range 37–77
Stage
 Metastatic 29 94
 Locally advanced 2 6
WHO performance status
 0 16 52
 1 11 35
 2 4 13
Histology
 Adenocarcinoma 30 97
 Acinar cell carcinoma 1 3
Prior therapy
 First line 15 48
  Neoadjuvant CRT 1 3
  Adjuvant gemcitabine 1 3
 Second line 16 52
  Adjuvant gemcitabinea 5 16
  Palliative 11 35
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survival rate was 38.7 % and the median overall survival 
was 8.9 months (95 % CI 4.6–13.1 months) (Fig. 2). Over-
all survival was 12.4 months (95 % CI 10.2–14.6) and 
5.9 months (95 % CI 1.6–10.2) in first (n = 15)- and sec-
ond-line patients (n = 16), respectively. Median progres-
sion-free survival (PFS) was 3.6 months (95 % CI 1.9–5.3), 
5.7 months (95 % CI 2.0–9.5) and 2.3 months (95 % CI 
2.2–2.5) for all, first- and second-line patients, respectively.
Discussion
In this phase II study, exploring the combination of capecit-
abine with the oral mTOR inhibitor everolimus in patients 
with advanced pancreatic cancer moderate treatment activ-
ity was observed with a response rate (RR) of 6.5 % and an 
overall survival (OS) of 8.9 months.
As a single-arm phase II study, the contribution of 
everolimus in this treatment regimen is difficult to deter-
mine. However, our results can be compared with previous 
studies using capecitabine as monotherapy. A RR of 7.1 % 
was seen in a study of capecitabine (1250 mg/m2 BID) in 
42 patients with advanced pancreatic cancer as first-line 
treatment [30]. A randomized phase II study with pre-
treated pancreatic cancer patients showed a RR of 9.4 % 
for the 32 patients in the capecitabine (1250 mg/m2 BID) 
control arm [34].
The endpoint OS in non-randomized phase II studies, 
should be used with care, because of the constraints of his-
torical control groups and inadequate sample sizes, espe-
cially in subgroup analyses. Nevertheless, the median OS 
of 8.9 months in the entire cohort, 12.4 months in first-line 
patients and 5.9 months in second-line patients reported 
in this study are encouraging. The overall survival for 
capecitabine monotherapy in first-line patients reported 
by Cartwright et al. [30] was 5.9 months (95 % CI 2.8–
9.0 months). And OS in second-line patients, reported by 
Bodoky et al. [34] was 5.0 months. Therefore, the addition 
of everolimus to capecitabine might enhance efficacy of 
capecitabine monotherapy, especially in first-line patients.
The most commonly reported treatment-related clinical 
side effects were stomatitis, fatigue and hand-foot syndrome. 
Table 2  Treatment administration of the combination of everolimus 
and capecitabine
SD standard deviation
Evaluable patients (N = 31)
No. of treatment cycles
 Median 3
 Range 1–15
No. of treatment days with everolimus




No. of patients (%)
 Dose reduction due to toxicity 5 (16)
 Temporary treatment disruption due to toxicity 6 (19)
Capecitabine dose delivery
No. of patients (%)
 Dose reduction due to toxicity 14 (45)
 Temporary treatment disruption due to toxicity 15 (48)
Table 3  Treatment-related grade 1–2 and grade 3–4 adverse events
GGT gamma-glutamyltransferase, ASAT aspartate aminotransferase, 
ALAT alanine aminotransferase, AP alkaline phosphatase
a
 Mucositis including aphthous ulcers and stomatitis
b




No. of patients N = 31 (100)
CTC grade Grade 1–2 Grade 3–4
Adverse event
Mucositisa 18 (58) 1 (3)
Fatigue 17 (55)
Hand-foot syndrome 9 (29) 5 (16)
Diarrhea 13 (42) 2 (6)
Nausea 16 (52)
Skinb 20 (65) 1 (3)
Anorexia 8 (26)
Vomiting 12 (39) 1 (3)
Neuropathy 7 (23)
Constipation 4 (13)




Anemia 25 (81) 1 (3)
Thrombocytopenia 14 (45) 2 (6)
Neutropenia 12 (39)
Clinical chemistry
Hyperglycemiac 13 (42) 14 (45)
AP 19 (61) 2 (6)
ASAT 11 (35)
ALAT 12 (39)
Hypokalemia 10 (32) 5 (16)
Hyponatremia 7 (23)
Hypertriglyceridemia 7 (23)
GGT 13 (42) 9 (29)
Bilirubin 4 (13) 1 (3)
Hypercholesteremia 3 (10)
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Although stomatitis is a common adverse event of both 
capecitabine and everolimus as single agent, this overlapping 
toxicity remained mild to moderate in severity in this study 
and led to dose reduction in only one patient. We assume at 
most marginally additive toxicity of capecitabine to everoli-
mus since the frequency of stomatitis in this study was simi-
lar to that in studies with single-agent everolimus [30, 34, 
35]. The frequency of fatigue was increased compared with 
single-agent studies of either agent, suggesting an additive 
toxic effect of the combination. An alternative explanation for 
the increased incidence of fatigue might be disease related. 
Patients with pancreatic cancer have a high probability to 
develop disease-related fatigue [36]. Hand-foot syndrome 
can be solely attributed to capecitabine, since this has not 
been observed before in single-agent everolimus trials. This 
well-known side effect of capecitabine resulted in dose reduc-
tions of capecitabine in 45 % of the patients, which is only 
10 % higher than in a previous study with colorectal cancer 
patients receiving capecitabine monotherapy and might be 
related to the combinatory effects of the study drugs [37]. 
Grade 3 hyperglycemia was seen in 45 % of the patients 
in the non-fasting blood draws, which is more than seen in 
everolimus monotherapy in this patient group (18 %), but it 
mostly remained at manageable levels and did not lead to 
dose reductions [14]. Other adverse events included diarrhea, 
anorexia, taste loss, neuropathy and skin rash, but remained 
non-severe. The frequency and severity of toxicity confirmed 
the data from our previous phase I study [27].
In contrast to the outlined acceptable toxicity findings, a 
prior phase I study that combined the mTOR inhibitor tem-
sirolimus and 5-FU demonstrated dose limiting stomatitis 
and hematological toxicity, and in the expansion cohort, 
two patients died due to mucositis with bowel perfora-
tion [38]. An explanation for this difference could be dose 
related. The dose of temsirolimus in the expansion cohort 
of that phase I study was 45 mg/m2 per week, while the 
recommended dose used as monotherapy in renal cell car-
cinoma is 25 mg per week. The phase II study of capecit-
abine (650 mg/m2 BID) and everolimus (5 mg BID) in 
gastric cancer patients, showed less toxicity, especially in 
all grade hand-foot syndrome (35 vs 13 %), fatigue (55 vs 
6 %) and diarrhea (48 vs 22 %) [26]. This is probably due 
to the lower dose of capecitabine and the different disease.
Recently, the combination of conventional chemotherapy 
(gemcitabine) with everolimus is examined as first-line treat-
ment for pancreatic cancer patients [39]. Everolimus 5 mg 
BID could not be combined with full-dose gemcitabine, as the 
maximum tolerated dose was already met at 400 mg/m2 [39]. 
In comparison with the present study, this might indicate that 
for combining everolimus with conventional chemotherapy, 
capecitabine is easier to administer at therapeutical doses.
Table 4  Response rates for the entire cohort (N = 31)
Per protocol radiological response evaluable patients (N = 22). Nine patients discontinued the study before radiological tumor response evalua-
tion was performed (PD)
PD progressive disease, PR partial remission, SD stable disease
Type of response Entire cohort (n = 31) First line (n = 15) Second line (n = 16)
PR 2 65 % 2 13 % 0 0 %
SD 10 32 % 8 53 % 2 13 %
PD 19 61 % 5 33 % 14 87 %
Fig. 1  Best confirmed change from baseline in sum of longest diam-
eters of target lesion size (%), by RECIST 1.0
Fig. 2  Kaplan–Meier curve of overall survival
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In conclusion, we showed that continuous everolimus 
5 mg BID combined with capecitabine 1000 mg/m2 for 
14 days every 3 weeks is a feasible and moderately effica-
cious outpatient oral treatment regimen, but only in first-
line pancreatic cancer patients.
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